Hong-Wu Chen

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells”.

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells

Nature Communications(2020)10.1038/s41467-020-18245-7

N/A

0DataRank · unranked

149 citations

Bowen Xie, Jie Huang, Ming Fan, Aijun Wang, Cheikh Menaa +27 more

S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis

Chemico-Biological Interactions(2020)10.1016/j.cbi.2020.108965

N/A

0DataRank · unranked

29 citations

Jianwei Zheng, June X. Zou, Jianzhen Xu, Fanghai Han, Songtao Xiang +4 more

RORγ is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases

Biochemical Pharmacology(2021)10.1016/j.bcp.2021.114725

N/A

0DataRank · unranked

32 citations

Nianxin Yang, Xiong Zhang, Hong-Wu Chen, Hongye Zou

Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling

Cancers(2021)10.3390/cancers13071672

N/A

0DataRank · unranked

14 citations

Zenghong Huang, Junjian Wang, Zhao Ma, Joy C. Yang, Eva Corey +4 more

Nuclear receptor RORγ inverse agonists/antagonists display tissue- and gene-context selectivity through distinct activities in altering chromatin accessibility and master regulator SREBP2 occupancy

Pharmacological Research(2022)10.1016/j.phrs.2022.106324

N/A

0DataRank · unranked

11 citations

Yatian Yang, Zhenrui Shi, Xuesong Wu, Ruiwu Liu, Ai‐Ming Yu +2 more

Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer

Acta Pharmaceutica Sinica B(2023)10.1016/j.apsb.2023.07.011

N/A

0DataRank · unranked

14 citations

Mei‐Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara +4 more

Natural compounds ursolic acid and digoxin exhibit inhibitory activities to cancer cells in RORγ-dependent and -independent manner

Frontiers in Pharmacology(2023)10.3389/fphar.2023.1146741

N/A

0DataRank · unranked

9 citations

Yatian Yang, Hong-Wu Chen, Hongye Zou

Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogramming

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2411321121

N/A

0DataRank · unranked

12 citations

Xiong Zhang, Demin Cai, Xingling Zheng, Xuan Zhao, June X. Zou +12 more

Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer

Nature Communications(2024)10.1038/s41467-024-50459-x

N/A

0DataRank · unranked

10 citations

Joy C. Yang, Bo Chen, Shu Ning, Xiong Zhang, Leyi Wang +16 more

Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors

Acta Pharmaceutica Sinica B(2025)10.1016/j.apsb.2025.01.007

N/A

0DataRank · unranked

12 citations

Yatian Yang, Hongye Zou, Yang Yang, Xingling Zheng, Eva Corey +6 more